Coronavirus & infrastructure: Trial by fire
Conservative investors who trust infrastructure for its stability have received a rude awakening with COVID-19. With appetite for the asset class unchanged, it’s time to get smart about risk
Macro events normally strike the most vulnerable parts of the economy first, chipping away at banks, factories, and retail until, after months of losses, the sturdier stuff of infrastructure finally sees...
More on Infrastructure
Latest News
Corporate VCs & climate change: Good citizens
Increased climate change awareness on a corporate level is leading to more investment – either direct or through funds – in start-ups that offer mitigation solutions. Asia is a key geography
Panacea leads $40m Series C for China's XWPharma
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Tencent backs Chinese healthcare cloud services platform
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.
Chinese mouse-based drug testing specialist raises $143m
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.